Blood

Vol. 145, Issue 6 Issue 6 2025
16
Articles

Articles in this Issue

Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML

Warren Fiskus, Christopher P. Mill, Prithviraj Bose et al. Feb 06, 2025 pp. 612-624 10.1182/blood.2024026388

Abstract Rising blast percentage or secondary acute myeloid leukemia (sAML) transformation in myeloproliferative neoplasms (MPNs) leads to JAK1/2 inhibitor (JAKi) therapy resistance...

The dark zone of CNS relapse in DLBCL

Kieron Dunleavy Feb 06, 2025 pp. 552-554 10.1182/blood.2024027329

The hepcidin-ferroportin axis modulates liver endothelial cell BMP expression to influence iron homeostasis in mice

Allison L. Fisher, Sydney Phillips, Chia-Yu Wang et al. Feb 06, 2025 pp. 625-634 10.1182/blood.2024024795

Abstract The liver hormone hepcidin regulates systemic iron homeostasis to provide enough iron for vital processes while limiting toxicity. Hepcidin acts by degrading its receptor fe...

BMPs and iron: the ins and outs

Nermi L. Parrow, Robert E. Fleming Feb 06, 2025 pp. 557-558 10.1182/blood.2024027052

No exit: targeting RNA export in T-cell malignancy

Katherine L. B. Borden Feb 06, 2025 pp. 554-556 10.1182/blood.2024027322

CNS relapse in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> rearrangements and dark-zone signature–expressing DLBCL

Waleed Alduaij, Aixiang Jiang, Diego Villa et al. Feb 06, 2025 pp. 590-596 10.1182/blood.2024025725

Abstract High-grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBCL-DH-BCL2), or “double-hit lymphoma,” has been associated with a high risk of central nervous system (CNS) r...

The GATA-3–dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas

Nermin Kady, Suhaib Abdelrahman, Ahmar M. Rauf et al. Feb 06, 2025 pp. 597-611 10.1182/blood.2024025484

Abstract The transcription factor GATA-binding protein 3 (GATA-3) and the transcriptional program it regulates have emerged as oncogenic drivers across diverse T-cell lymphomas (TCLs...

Menin inhibitors in the treatment of acute myeloid leukemia

Gerwin Huls, Carolien M. Woolthuis, Jan Jacob Schuringa Feb 06, 2025 pp. 561-566 10.1182/blood.2024026232

Abstract Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the (oligo)clonal expansion of myeloid progenitor cells. Despite advances in treatmen...

How I treat blastic plasmacytoid dendritic cell neoplasm

Mohamed A. Kharfan-Dabaja, Andrew A. Lane, Naveen Pemmaraju Feb 06, 2025 pp. 567-576 10.1182/blood.2024024262

Abstract Historically, treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN) were limited to conventional chemotherapy, adopted from regimens used to treat acute...

Antibodies to PF4 in severe COVID-19: same but different

Philip Young-Ill Choi, Imogen Mitchell Feb 06, 2025 pp. 559-560 10.1182/blood.2024027599

Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia

Marlise R. Luskin, Mark A. Murakami, Julia Keating et al. Feb 06, 2025 pp. 577-589 10.1182/blood.2024025800

Abstract Dasatinib is an effective treatment for Philadelphia chromosome–positive (Ph+) acute leukemia, but some patients develop resistance. Combination treatment with dasatinib and...

Acute myeloid leukemia with <i>BCL6</i> and <i>KMT2A</i> dual rearrangements

Qiudan Shen, Shimin Hu Feb 06, 2025 pp. 652-652 10.1182/blood.2024027210

β-Thalassemia minor is associated with high rates of worsening anemia in pregnancy

Arielle L. Langer, Brynn B. Goggins, Erica B. Esrick et al. Feb 06, 2025 pp. 648-651 10.1182/blood.2024026736

Abstract We identified 347 pregnancies in patients with β-thalassemia minor. Hemoglobin was &amp;lt;9 g/dL in 31% during third trimester and 7.6% at delivery. Postpartum hemorrhage o...

De-JAKing resistance with CDK7 inhibitors in post-MPN sAML

Lucio H. Castilla Feb 06, 2025 pp. 556-557 10.1182/blood.2024027365

Asciminib for Ph+ ALL: a step forward?

Fabian Lang, Oliver G. Ottmann Feb 06, 2025 pp. 551-552 10.1182/blood.2024027064

Prothrombotic antibodies targeting the spike protein's receptor-binding domain in severe COVID-19

Wen Zhu, Yongwei Zheng, Mei Yu et al. Feb 06, 2025 pp. 635-647 10.1182/blood.2024025010

Abstract Thromboembolic complication is common in severe coronavirus disease 2019 (COVID-19), leading to an investigation into the presence of prothrombotic antibodies akin to those...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page